🇧🇷Brazil

Multas ANVISA por Falha no Controle de Estoque (ANVISA Fines for Inventory Control Violations)

2 verified sources

Definition

ANVISA inspections assess whether pharmacies maintain accurate, time-stamped inventory records and evidence of FIFO/PEPS compliance. Source [9] references 'Gestão do Estoque Regulatório' as a systematic ANVISA requirement. Manual systems fail to generate audit trails, exposing pharmacies to compliance violations.

Key Findings

  • Financial Impact: Estimated ANVISA fine: R$ 5,000–100,000+ per violation. Average fine for first-time inventory control violation: R$ 10,000–50,000. Repeated violations: escalation to license suspension (potentially R$ 500,000+ revenue impact annually).
  • Frequency: Variable; ANVISA inspections typically occur 1–3 years apart per location, but triggered by customer complaints or prior violations
  • Root Cause: Inadequate documentation systems; lack of time-stamped transaction logs; manual inventory reconciliation not linked to sales records; expired products remaining on shelves

Why This Matters

The Pitch: Brazilian pharmacies face regulatory audits with fines ranging R$ 1,000–100,000+ for inventory control gaps. Automated expiration monitoring and audit-ready logs eliminate violation risk.

Affected Stakeholders

Pharmacy Owner, Compliance Officer, Pharmacy Manager

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

Perda por Vencimento de Medicamentos (Product Expiration Waste)

Estimated: R$ 2,000–25,000 annually per pharmacy (2–5% of typical inventory value of R$ 100,000–500,000). Pharmacy chains with 10+ locations: R$ 20,000–250,000+ annually.

Custo de Gestão Manual de Estoque (Manual Inventory Management Labor Cost)

Estimated: R$ 1,000–4,000 monthly per pharmacy location (20–40 hours × R$ 50–100/hour). Multi-location chains: R$ 10,000–40,000+ monthly for 10 locations.

Ruptura de Estoque e Perda de Vendas (Stock-Out-Induced Revenue Loss)

Estimated: 5–10% of monthly revenue per location. Average pharmacy daily revenue: R$ 5,000–20,000. Monthly loss: R$ 7,500–60,000 per pharmacy.

Erro de Decisão de Compra por Falta de Visibilidade de Dados (Poor Purchasing Decisions Due to Data Gaps)

Estimated: 10–20% of annual inventory value tied up in excess slow-moving stock. Average pharmacy inventory: R$ 100,000–500,000. Excess working capital tied up: R$ 10,000–100,000+. Carrying cost (rent, shrinkage, deterioration): 15–25% annually = R$ 1,500–25,000 per pharmacy annually.

Multa por Violação de LGPD e Privacidade do Consumidor

R$ 8,497,500.00 (confirmed fine); potential industry exposure: R$ 50,000–R$ 3,000,000 per administrative proceeding depending on scale and intent.

Risco de Recusa de Cobertura de Plano de Saúde por Violação de Dados Sensíveis

Per-customer litigation cost: R$ 10,000–R$ 50,000; churn impact: 2–5% customer base loss annually; class action risk: R$ 5,000,000+.

Request Deep Analysis

🇧🇷 Be first to access this market's intelligence